Nanobiotix (NASDAQ:NBTX) Stock Price Expected to Rise, Guggenheim Analyst Says

Nanobiotix (NASDAQ:NBTX) had its price target upped by stock analysts at Guggenheim from $8.00 to $26.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 24.70% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. TD Cowen initiated coverage on shares of Nanobiotix in a research report on Friday. They set a “buy” rating on the stock. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Trading Down 0.9%

NBTX opened at $20.85 on Friday. The business’s 50-day simple moving average is $21.64 and its 200 day simple moving average is $17.40. Nanobiotix has a 52-week low of $2.95 and a 52-week high of $30.35.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.